Optimizing the Internal Medicine Residency Recruitment Process: A National Survey of Program Directors and Next Steps - 09/04/24
, Vera P. Luther, MD b, Michelle Sweet, MD c, Jaya M. Raj, MD d, Whitney Harper, EdD e, Alpesh N. Amin, MD, MBA f, Kristen Lewis, MD a, Linda Harris, AAS g, Cindy J. Lai, MD hEsquema
| Funding: None. |
|
| Conflict of Interest: None except for the following: ANA reports PI or co-I of clinical trials sponsored by NIH/NIAID, NeuroRx Pharma, Pulmotect, Blade Therapeutics, Novartis, Takeda, Humanigen, Eli Lilly, PTC Therapeutics, OctaPharma, Fulcrum Therapeutics, Alexion; Speaker and/or consultant for Pfizer, Salix, Alexion, AstraZeneca, Bayer, Ferring, Seres, Spero, Eli Lilly, Nova Nordisk, Gilead, Renibus, GSK, Dexcom, HeartRite, Aseptiscope, unrelated to the current work. |
|
| Authorship: All authors had a role in writing this manuscript. |
Vol 137 - N° 4
P. 370-376 - avril 2024 Regresar al númeroBienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
¿Ya suscrito a @@106933@@ revista ?
